Sinikka Oksa

Pori, Finland

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications

Is it safe to operate selected low-risk endometrial cancer patients in secondary hospitals?

Is it safe to operate selected low-risk endometrial cancer patients in secondary hospitals?

Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
Published: December 22, 2023

Extensive mutational ctDNA profiles reflect High-grade serous cancer tumors and reveal emerging mutations at recurrence.

Extensive mutational ctDNA profiles reflect High-grade serous cancer tumors and reveal emerging mutations at recurrence.

Journal: Translational oncology
Published: July 17, 2023

A Novel Two-Lipid Signature Is a Strong and Independent Prognostic Factor in Ovarian Cancer.

A Novel Two-Lipid Signature Is a Strong and Independent Prognostic Factor in Ovarian Cancer.

Journal: Cancers
Published: February 23, 2021

A longitudinal analysis of CA125 glycoforms in the monitoring and follow up of high grade serous ovarian cancer.

A longitudinal analysis of CA125 glycoforms in the monitoring and follow up of high grade serous ovarian cancer.

Journal: Gynecologic oncology
Published: November 16, 2019

18F-FDG-PET/CT based total metabolic tumor volume change during neoadjuvant chemotherapy predicts outcome in advanced epithelial ovarian cancer.

18F-FDG-PET/CT based total metabolic tumor volume change during neoadjuvant chemotherapy predicts outcome in advanced epithelial ovarian cancer.

Journal: European journal of nuclear medicine and molecular imaging
Published: October 17, 2017

Postoperative human epididymis protein 4 predicts primary therapy outcome in advanced epithelial ovarian cancer.

Postoperative human epididymis protein 4 predicts primary therapy outcome in advanced epithelial ovarian cancer.

Journal: Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
Published: February 21, 2017

18F-FDG-PET/CT can identify histopathological non-responders to platinum-based neoadjuvant chemotherapy in advanced epithelial ovarian cancer.

18F-FDG-PET/CT can identify histopathological non-responders to platinum-based neoadjuvant chemotherapy in advanced epithelial ovarian cancer.

Journal: Gynecologic oncology
Published: June 17, 2015

Serum HE4 and CA125 as predictors of response and outcome during neoadjuvant chemotherapy of advanced high-grade serous ovarian cancer.

Serum HE4 and CA125 as predictors of response and outcome during neoadjuvant chemotherapy of advanced high-grade serous ovarian cancer.

Journal: Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
Published: June 17, 2014

A prospective comparison of integrated FDG-PET/contrast-enhanced CT and contrast-enhanced CT for pretreatment imaging of advanced epithelial ovarian cancer.

A prospective comparison of integrated FDG-PET/contrast-enhanced CT and contrast-enhanced CT for pretreatment imaging of advanced epithelial ovarian cancer.

Journal: Gynecologic oncology
Published: June 03, 2013

Is perioperative visual estimation of intra-abdominal tumor spread reliable in ovarian cancer surgery after neoadjuvant chemotherapy?

Is perioperative visual estimation of intra-abdominal tumor spread reliable in ovarian cancer surgery after neoadjuvant chemotherapy?

Journal: Gynecologic oncology
Published: September 24, 2012
Showing 1-10 of 10

Last Updated: 09/26/2026